Related Experiment Videos
GP IIb/IIIa blockade in elective percutaneous coronary intervention
J P Dery1, R A Harrington, J E Tcheng
1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA.
Current Pharmaceutical Design
|February 18, 2004
Summary
Platelet GP IIb/IIIa inhibitors reduce ischemic complications and improve survival in patients undergoing percutaneous coronary intervention (PCI). Despite evidence, their use in PCI remains inconsistent, warranting further discussion.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Platelet GP IIb/IIIa inhibitors are established in reducing ischemic complications during percutaneous coronary intervention (PCI).
- Recent data indicate these inhibitors also enhance short- and long-term survival post-PCI.
Purpose of the Study:
- To review the scientific basis for using GP IIb/IIIa inhibitors in PCI.
- To discuss controversies surrounding their administration in elective PCI.
Main Methods:
- Review of cumulative scientific evidence over the past ten years.
- Analysis of mortality data from over 20,000 patients in randomized clinical trials.
Main Results:
- Consistent evidence supports GP IIb/IIIa inhibitors in reducing ischemic events.
- Mortality data suggest improved survival rates with GP IIb/IIIa blockade post-PCI.
Conclusions:
- GP IIb/IIIa inhibitors are crucial for managing PCI patients.
- Inconsistent administration highlights a need to address clinical practice gaps and controversies.